HomeLBank Stocks
Insmed Inc
Insmed Inc

Insmed Inc (INSM)

24HHigh$149.0724HLow$118.00
$144.25
+0.21%

Last updated: 2026-11-20 10:30:33

K-Line Chart, actual market data is subject to the trading page.

Key Data

Prev. Open
$119.50
Prev. Close
$144.25
Prev. Day's Range
$118.00 - $149.07
52W Range
$90.39 - $212.75
Trading Volume
13.4M
MC
$26.282B
P/E Ratio
--
EPS
$-2.81

Company Overview

NASDAQ

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Headquarters700 US HIGHWAY 202/206, BRIDGEWATER, NJ, UNITED STATES, 08807
CountryUSA
Listing Date1991-02-15
Fiscal Year Ended2026-09-30
Shares Outstanding219.38M
CIK Code1104506

Financial Metrics

Indicator2026-06-302026-03-312025-12-312025-09-30
Income$425.486M$305.964M$263.843M$142.342M
Operating Expenses$67.212M$49.501M$44.22M$29.365M
Net Income-$13.242M-$163.563M-$328.485M-$370.021M
Net Profit Margin-3.1%-53.5%-124.5%-260.0%
Earnings Per Share--$-0.76$-1.54$-1.75
EBITDA$14.16M-$136.323M-$302.15M-$345.665M
Effective Tax Rate-16.4%-0.9%-0.5%-0.4%

FAQ

Insmed Incorporated focuses on developing and commercializing therapies for serious and rare diseases. Its core products and pipeline are designed to address conditions with significant unmet medical needs, particularly in respiratory diseases like non-tuberculous mycobacterial (NTM) lung infections.
Insmed operates within the Healthcare sector, specifically in the Biotechnology industry. The company is involved in developing innovative therapeutic solutions targeting rare and life-impacting diseases.
Insmed’s revenue is primarily driven by the commercialization of its FDA-approved therapies, such as ARIKAYCE for treating NTM lung infections caused by Mycobacterium avium complex. Revenue growth also depends on expanding its market reach and advancing its clinical pipeline.
Investing in Insmed carries risks, including the uncertainty of clinical trial outcomes, regulatory approvals, and competition in the biotechnology space. Additionally, as a company focused on rare diseases, market size and adoption rates may impact its financial performance.
Insmed stands out by focusing on therapies that address rare diseases with significant unmet needs, particularly in the respiratory space. Its expertise in developing innovative drug delivery solutions and securing FDA approvals for niche treatments positions it uniquely within the biotechnology landscape.
No, Insmed does not currently pay dividends. As a growth-oriented biotechnology company, it reinvests earnings into research, development, and the commercialization of new therapies to drive long-term growth.
Insmed has a robust pipeline targeting rare and serious diseases. While the success of its clinical trials could greatly enhance growth opportunities, trial outcomes are inherently uncertain and subject to regulatory scrutiny, which presents both opportunities and risks for investors.
Regulatory decisions play a critical role in Insmed’s stock performance. FDA approvals, expanded label indications, or setbacks in clinical trials can significantly influence market sentiment regarding the company’s growth potential and valuation.
Risk Warning
  1. 1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
  2. 2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
  3. 3.The information contained on this page is for reference only and does not constitute any investment advice.